Clinical Trials Logo

Pancreatic Cancer Non-resectable clinical trials

View clinical trials related to Pancreatic Cancer Non-resectable.

Filter by:

NCT ID: NCT03941093 Active, not recruiting - Clinical trials for Pancreatic Cancer Non-resectable

Evaluation of Efficacy and Safety of Neoadjuvant Treatment With Pamrevlumab in Combination With Chemotherapy (Either Gemcitabine Plus Nab-paclitaxel or FOLFIRINOX) in Participants With Locally Advanced Pancreatic Cancer

LAPIS
Start date: May 10, 2019
Phase: Phase 3
Study type: Interventional

This is a Phase 3, randomized, double-blind trial to evaluate the efficacy and safety of neoadjuvant treatment with pamrevlumab or placebo in combination with either gemcitabine plus nab-paclitaxel (G/NP) or FOLFIRINOX in the treatment of participants with locally advanced, unresectable pancreatic cancer.

NCT ID: NCT03590275 Completed - Clinical trials for Pancreatic Cancer Non-resectable

Observational Retrospective Study of Evaluation of Prognostic Factors in Advanced Pancreatic Cancer Patients Treated With FOLFIRINOX

HOPE
Start date: October 2, 2017
Phase:
Study type: Observational

The aim of this study is to identify new prognostic factors in patients affected by advanced pancreatic carcinoma treated with first line chemotherapy with FOLFIRINOX regimen. Primary objective is the identification of clinical, laboratory and pathologic factors affecting overall survival of these patients.

NCT ID: NCT03165591 Recruiting - Clinical trials for Pancreatic Cancer Non-resectable

Open Label Immunotherapy Trial of Inoperable Pancreatic Cancer

V3-P
Start date: May 1, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

Pancreatic cancer (PDA) is the most lethal form of cancer, and the fourth-leading cause of cancer-related death in the United States, with a survival rate of less than 7%.There are currently no treatments found to be effective for patients with advanced disease who are ineligible for surgery, a prognosis representing the majority of pancreatic cancer diagnoses. Pancreatic cancer is not amenable to chemotherapy as compared to other cancer types, leaving patients with practically no options except surgery. We have made oral tableted therapeutic vaccine, V3-P, derived from pooled blood of patients with PDA in line with similar highly promising approach we have adopted for patients with hepatocellular carcinoma (HCC) and cholangiocarcinoma (CAA). Patients with PDA will be given one tablet per day of V3-P and followed up to see the outcome.

NCT ID: NCT02128100 Completed - Clinical trials for Pancreatic Cancer Non-resectable

Effects of Folfirinox and Stereotactic Body Radiation Therapy for Advanced Pancreatic Cancer

BCC-RAD-13
Start date: September 19, 2014
Phase: Phase 2
Study type: Interventional

This study wants to find out how safe and effective the use of Folfirinox combined with Stereotactic Body Radiation Therapy )(SBRT) is for the treatment of pancreatic cancer.

NCT ID: NCT01887041 Terminated - Advanced Cancer Clinical Trials

Quality of Life After Biliodigestive Anastomosis (BDA) or Stents to Treat Biliary Obstruction in Pancreas Cancer

BYPAPA
Start date: January 2010
Phase: Phase 4
Study type: Interventional

To compare the quality of life (QoL) in patients receiving a bilioenteric anastomosis vs. endoscopical stenting for palliation of biliary obstruction due to locally unresectable or metastatic pancreatic cancer. In the past, endoscopy seems to have been favoured based on older studies, but with new chemotherapeutic regimens available, the likelihood to experience stent complications has increased. Therefore, the issue as to which palliation should be favoured has to be reconsidered.